This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hemophilia BB형혈우병 (비형 혈우병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D67 (hereditary factor IX deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsHemophilia B, Christmas disease, Hereditary factor IX deficiency, plasma thromboplastin component deficiency (PTC deficiency)
C. Adult onsetLikelihood of first onset in adulthood not low — in mild cases (FIX 5–40%), which account for about 30–40% of the total, first diagnosis after age 18 without surgery, tooth extraction, or trauma is common; the FIX Leyden variant shows an unusual course, converting from severe in childhood to spontaneously mild after puberty, with only relatively mild symptoms in adulthood.
1. History1952 simultaneous naming of Christmas disease and PTC deficiency, F9 cloning, recombinant FIX, EHL, emicizumab, gene therapy
2. CausesF9 (Xq27.1) point mutations (84%), deletions (11%), frameshift, nonsense, Leyden-type promoter variants
3. GeneticsF9 Xq27.1, 34kb, 8 exons, 415aa, 55kDa; Leyden and Padua specific variants; inhibitor risk differs by variant
4. Epidemiology1/25,000–30,000 male births, 160,000 worldwide, 750 in KBDR, severe 30%, moderate 30%, mild 40%
5. PathophysiologyFIXa, FVIIIa, Ca2+, and phospholipid tenase complex → FX activation → thrombin generation step blocked
6. SymptomsSevere spontaneous hemarthrosis (knee, elbow, ankle), muscle hematoma (iliopsoas), intracranial hemorrhage; distinctive course of the Leyden type
7. SignsProlonged APTT, decreased FIX:C, normal PT, joint swelling and warmth, inhibitors 3–5%
8. ScreeningNewborn FIX:C with family history (retest at 6 months), carrier F9 NGS, APTT → FIX:C
9. DiagnosisAPTT → FIX:C (one-stage/chromogenic) → F9 gene analysis (8 exons + promoter) → inhibitors (Bethesda method)
10. TreatmentSHL and EHL FIX, emicizumab, fitusiran, gene therapy (Hemgenix), bypassing therapy with inhibitors
11. PrognosisNormal life expectancy, inhibitors 3–5%, good adult prognosis for the Leyden type, long-term monitoring after gene therapy
12. PreventionGenetic counseling, carrier F9 testing, prenatal diagnosis (CVS/amniocentesis), PGT, early primary prophylaxis
13. References10 major international guidelines and original articles

1. History

Hemophilia is one of the oldest hereditary bleeding diseases recorded by humankind. The Talmud of the 2nd century BC describes cases of exemption from circumcision because of recurrent bleeding, and the 18th-century American John Otto described in 1803 that a bleeding tendency affecting only males in certain families is inherited through the maternal line. However, it was only in the mid-20th century that hemophilia was found to consist not of a single disease but of at least two independent types.

1952: Simultaneous discovery of Christmas disease and PTC deficiency

1952 was the year in which two independent, historic discoveries were made almost simultaneously in the history of hemophilia B. Rosemary Biggs, Alan Douglas, Reginald Macfarlane, and colleagues at the University of Oxford, UK, reported in the December 27, 1952 issue of the British Medical Journal that a series of patients who had until then been misdiagnosed with hemophilia A were actually deficient in a different clotting factor. They named the disease Christmas disease after a 5-year-old patient, Stephen Christmas. The fact that the paper was published in the BMJ just before Christmas also helped the name become naturally established.

At almost the same time, Paul Aggeler and colleagues at the University of California independently discovered the same disease and, emphasizing that the deficient factor is a component required for the generation of plasma thromboplastin, named it plasma thromboplastin component (PTC) deficiency (Proc Soc Exp Biol Med. 1952;79:692-694). The international committee on coagulation factor nomenclature later unified this factor as Factor IX, and the disease name was standardized as Hemophilia B.

Building the molecular biological foundation: 1980s–1990s

In 1982, Kazuo Kurachi and Earl Davie of the University of British Columbia, Canada, first determined the mRNA sequence of human FIX (Proc Natl Acad Sci USA. 1982;79:6461-6464), making it possible to predict the amino acid sequence of the FIX protein. In 1985, the complete genomic structure of the F9 gene (Xq27.1, 34kb, 8 exons) was determined. On this molecular foundation, analysis of F9 gene mutations began systematically, and the molecular heterogeneity of hemophilia B began to be revealed.

In 1992, an important discovery elucidated the molecular basis of the FIX Leyden phenotype. Crossley et al. published in Science that mutations in the androgen response element region within the F9 promoter cause severe hemophilia in childhood, but that after puberty, as androgens increase, an alternative promoter or adjacent androgen response element is activated and FIX expression gradually recovers (Science. 1992;257:377-379). This discovery, a unique example of hormonal regulation of gene expression, also inspired the development of gene therapy strategies for hemophilia B.

Advances in treatment: from recombinant FIX to gene therapy

The transmission of HIV and hepatitis C through blood products in the 1990s prompted a shift in the paradigm of hemophilia treatment toward virus-inactivated plasma-derived products and recombinant products. In 1997, the US FDA approved the recombinant FIX BeneFIX (nonacog alfa) for the treatment of hemophilia B. The introduction of recombinant products was an important turning point that eliminated the risk of blood-borne infection while maintaining the efficacy of FIX replacement.

In the 2010s, extended half-life (EHL) FIX products were approved one after another, changing clinical practice. Alprolix (eftrenonacog alfa, FIX-Fc fusion protein, Sanofi), approved by the FDA in 2014, extended the FIX half-life to about 82 hours, enabling once-weekly or biweekly dosing. Idelvion (albutrepenonacog alfa, FIX-albumin fusion, CSL Behring), approved in 2016, allowed even longer intervals with a half-life of about 104 hours, and Rebinyn (nonacog beta pegol, PEG-FIX) was added in 2017. The introduction of EHL products greatly reduced the frequency of prophylactic injections, contributing substantially to reducing patient burden and the number of venous accesses.

In 2019, emicizumab began to be applied to hemophilia B as well. Emicizumab is a bispecific antibody that mimics FVIIIa function; rather than directly replacing FIX, it binds FIX (FIXa) and FX simultaneously and substitutes for the function of the tenase complex. It offered a meaningful alternative to FIX products, particularly for hemophilia B patients with inhibitors.

Fitusiran, whose clinical adoption expanded in 2025, is an RNAi therapeutic targeting antithrombin; by increasing thrombin generation, it is a treatment with a new mechanism applicable to both hemophilia A and B. It is clinically significant in that it can be used regardless of inhibitor status.

In gene therapy, in 2011 Adrian Nathwani and colleagues first achieved safe and effective FIX expression in patients with hemophilia B using an AAV8-FIX vector (N Engl J Med. 2011;365:2357-2365). Subsequently, etranacogene dezaparvovec (Hemgenix, CSL Behring), an AAV5 vector carrying the FIX Padua variant (p.Arg338Leu, with 8 times the activity of normal FIX), received FDA approval in November 2022, making the first gene therapy for hemophilia B clinically available. That type B achieved gene therapy approval before type A in the hemophilia field owes much to the small size of the F9 gene, which is technically advantageous for loading into AAV vectors.

2. Causes

Hemophilia B is an X-linked recessive hereditary bleeding disease in which mutations in the F9 gene (Xq27.1) cause reduced synthesis, impaired secretion, or functional defects of FIX, impairing blood coagulation. F9 gene mutations occur in very diverse forms.

Missense mutations are the most common type, accounting for about 84% of all F9 mutations. A single base change substitutes one amino acid for another, and the degree of protein dysfunction depends on the location of the mutation and the properties of the substituted amino acid. Missense mutations cause phenotypes ranging from mild to severe and can be either CRM+ dysfunctional types or general protein-reduction types.

Deletions account for about 11% of the total. Extensive deletions involving a single exon or multiple exons cause complete loss of functional FIX protein, which is associated with severe hemophilia B and a high risk of inhibitor development. Frameshift mutations and nonsense mutations also tend to completely block FIX protein synthesis, causing a severe phenotype.

FIX Leyden-type variants are an unusual type in which mutations are located in the promoter region of the F9 gene (at several positions such as -6, -20, and -26). These variants damage transcriptional regulatory elements bound by hepatocyte nuclear factor (HNF4α) or C/EBPα, causing severe hemophilia in childhood, but show a unique course in which FIX expression gradually recovers as androgen levels rise after puberty, converting to mild disease. In about 30% of all hemophilia B patients, the cause is a de novo mutation without a family history.

3. Genetics

The F9 gene is located at band 27.1 of the long arm of the X chromosome (Xq27.1), has a total size of about 34kb, and consists of 8 exons. The mature FIX protein, of 415 amino acids with a molecular weight of about 55kDa, is a vitamin K-dependent serine protease precursor synthesized in hepatocytes.

Genetic comparison with hemophilia A

CharacteristicsHemophilia A (F8)Hemophilia B (F9)
Gene locationXq28Xq27.1
Gene size186kb, 26 exons34kb, 8 exons
Protein size280kDa55kDa
Prevalence (male births)1/5,000~10,0001/25,000~30,000
Inhibitor incidence25~30%3~5%
Protein half-lifeAbout 12 hoursAbout 18–24 hours
Gene therapy vectorF8 difficult to load into AAV (large size)F9 easy to load into AAV (small size)

The domain structure of the FIX protein is arranged in the order signal peptide → propeptide → Gla domain → EGF-1 domain → EGF-2 domain → activation peptide → SP domain. Glutamic acid residues in the Gla domain are converted to γ-carboxyglutamic acid (Gla) by vitamin K-dependent carboxylase (GGCX), which is essential for FIX binding to phospholipid membranes.

FIX Leyden variants occur at several positions in the F9 promoter (-6 G→A, -20 T→A, etc.). FIX:C is very low in childhood (often below 1%), but after puberty androgen-induced F9 gene expression spontaneously raises FIX:C to 5–40%. As a result, the disease converts to mild hemophilia in adolescence and adulthood. FIX Padua (p.Arg338Leu) is a gain-of-function variant with FIX:C reaching 8 times normal or more, increasing thrombotic risk in otherwise healthy individuals. Loading this variant into a gene therapy vector allows therapeutically sufficient FIX activity with only a small amount of FIX expression, and it was used in etranacogene dezaparvovec (Hemgenix).

The risk of inhibitor development varies by mutation type. Patients with large deletions, nonsense mutations, and extensive frameshift variants have a high risk of inhibitor development, whereas those with missense mutations have a relatively low risk. When inhibitors develop in hemophilia B, ITI (immune tolerance induction) is less effective and may be accompanied by anaphylactic reactions or nephrotic syndrome, which differs from inhibitor management in hemophilia A.

4. Epidemiology

The prevalence of hemophilia B is about 1/25,000–30,000 male births, about 5 times rarer than hemophilia A (1/5,000–10,000). There are estimated to be about 160,000 patients with hemophilia B worldwide. According to the annual survey of the World Federation of Hemophilia (WFH), registered hemophilia B patients account for about 15–20% of all hemophilia patients. In Korea, about 750 hemophilia B patients are registered in the Korea Hemophilia Foundation database (KBDR).

The severity distribution is known to be severe (FIX:C below 1%) about 30%, moderate (FIX:C 1–5%) about 30%, and mild (FIX:C 5–40%) about 40%. Compared with hemophilia A, the proportion of mild cases is somewhat higher. In mild cases, diagnosis is not infrequently delayed until adulthood, and the disease may first be discovered on occasions such as surgery, trauma, or tooth extraction. Patients with the FIX Leyden variant are classified as severe in childhood but convert to mild in adulthood.

No marked differences in prevalence by race or region have been reported, but some specific variants are observed at higher frequency in certain populations because of founder effects. It is important that about 30% of all hemophilia B patients have sporadic disease due to de novo mutations and can develop the disease without a family history.

5. Pathophysiology

In the normal intrinsic coagulation pathway, FIX is activated by FXIa (intrinsic pathway) or the tissue factor-FVIIa complex (extrinsic pathway, so-called external activation). FIX in its inactive precursor (zymogen) state is converted to FIXaβ (the active form) when its activation peptide is removed by FXIa. FIXa forms the intrinsic tenase complex with FVIIIa (cofactor) and calcium ions (Ca²⁺) on negatively charged phospholipid membranes (mainly the surface of activated platelets).

This complex catalyzes the activation of FX to FXa, and when the complex forms, the reaction rate increases by about 100,000-fold or more compared with FIXa alone. FXa forms the prothrombinase complex with FVa (cofactor), Ca²⁺, and phospholipid, converting prothrombin (FII) to thrombin (FIIa). Thrombin polymerizes fibrinogen into fibrin and activates FXIII to strengthen fibrin cross-linking, forming a stable hemostatic clot.

In FIX deficiency, the key enzyme component of the intrinsic tenase complex is lacking or nonfunctional, so FXa generation is limited. This leads in turn to reduced thrombin generation, insufficient fibrin formation, and hemostatic failure. The lower the FIX:C, the lower the efficiency of the tenase complex and the more severe the bleeding tendency. In severe disease (FIX:C below 1%), spontaneous bleeding occurs, while in mild disease (5–40%) there is mild hemostatic failure that manifests only with strong provocation.

6. Symptoms

The clinical symptoms of hemophilia B are determined by the FIX:C level and accompanying bleeding-provoking factors.

In severe hemophilia B (FIX:C below 1%), the most characteristic symptom is hemarthrosis. Intra-articular bleeding recurs after minor impact or without an obvious cause, most commonly affecting the knees, elbows, and ankles. Recurrent hemarthrosis causes chronic hemophilic arthropathy, progressing through synovial thickening, iron deposition, cartilage erosion, and bone erosion, which is a major cause of movement disorders, chronic pain, and reduced quality of life.

Muscle hematomas can occur in any muscle, such as the thigh, calf, or forearm, but iliopsoas hematoma is particularly important. Iliopsoas hematoma can cause groin pain, a flexed hip posture, and sensory disturbances and weakness from femoral nerve compression, and the large blood loss can lead to hemodynamic instability. Intracranial hemorrhage is the most life-threatening complication and can occur in severe hemophilia B after head trauma or, rarely, spontaneously.

In moderate disease (FIX:C 1–5%), spontaneous bleeding after severe trauma occurs occasionally, and intermittent joint bleeding may occur. Delayed bleeding after surgery or tooth extraction is also common. In mild disease (FIX:C 5–40%), there is almost no spontaneous bleeding during daily activities, and abnormal bleeding occurs only with provoking factors such as tooth extraction, surgery, delivery, or considerable trauma.

The FIX Leyden variant shows a unique clinical course. In childhood (before puberty), FIX:C is below 1% and symptoms are the same as in severe hemophilia B, but as puberty begins, androgens restore FIX expression and FIX:C rises to mild levels (5–40%). In adulthood, some patients can lead a relatively normal daily life even without prophylaxis, but individualized management based on each patient's FIX:C level and bleeding history is needed.

In female carriers as well, FIX:C may be reduced to borderline levels (30–50%) because of skewed X-chromosome inactivation, and symptoms such as menorrhagia, excessive bleeding after surgery, and postpartum hemorrhage may occur.

7. Signs

The main laboratory signs of hemophilia B are as follows. Isolated APTT prolongation is the most characteristic laboratory finding. Because the extrinsic coagulation pathway (FVII) and the common pathway (FII, FV, FX, fibrinogen) are normal, the PT (prothrombin time) remains normal. Platelet count and function, bleeding time, and platelet aggregation tests are also normal. FIX:C is reduced below 40%, and FVIII:C is measured as normal (the key point of differentiation from hemophilia A).

In joints with a history of recurrent hemarthrosis, physical examination shows joint swelling, warmth, tenderness, and restricted range of motion. When chronic hemophilic arthropathy has progressed, joint deformity, muscle atrophy, and joint instability may occur. At muscle hematoma sites, local swelling, tenderness, and subcutaneous ecchymosis are observed, and when there is nerve compression, sensory disturbances and weakness accompany them.

When inhibitors (anti-FIX neutralizing antibodies) develop, FIX:C does not rise as expected despite administration of FIX concentrates, and bleeding becomes difficult to control. The incidence of inhibitors in hemophilia B is about 3–5%, lower than in hemophilia A, but treatment is particularly complex when they occur. Caution is needed when attempting ITI in hemophilia B patients with inhibitors, as anaphylactic reactions or nephrotic syndrome may occur.

8. Screening

Screening strategies for hemophilia B are divided into two approaches: symptom-based and family history-based.

Symptom-based screening: In male patients with symptoms such as joint bleeding, muscle hematoma, unexplained excessive bleeding, or delayed postoperative bleeding, start with APTT measurement. If the APTT is prolonged and the PT normal, proceed to measurement of individual coagulation factors (FVIII:C, FIX:C, FXI:C, etc.). Hemophilia B is diagnosed when FVIII:C is normal and FIX:C is below 40%.

Family history-based screening: When there is a family history of hemophilia B, FIX:C can be measured from the neonatal period. However, it is important that FIX:C is physiologically low in the neonatal period. At birth, FIX:C is only about 30–50% of the adult normal value and reaches adult levels only at 6 months of age. Therefore, to distinguish whether a low neonatal FIX:C is due to hemophilia B or to a physiological decrease, FIX:C remeasurement after 6 months of age is needed. When the causative variant in the family is known, F9 gene analysis of cord blood or peripheral blood allows confirmation even in the neonatal period.

Screening of carrier females: F9 gene analysis (NGS or family variant-specific testing) is performed in the mothers, sisters, daughters, and other relatives of patients with hemophilia B. FIX:C is also measured in carrier females to assess bleeding risk. Carrier females with FIX:C below 50% may need a FIX replacement plan before surgery or delivery.

9. Diagnosis

The diagnosis of hemophilia B integrates three levels: clinical, laboratory, and genetic.

Step 1: APTT measurement and individual factor analysis — After confirming a prolonged APTT and normal PT, FVIII:C and FIX:C are measured. Hemophilia B is suspected when FVIII:C is normal and FIX:C is below 40%. It is recommended that FIX:C be measured by both the one-stage assay and the chromogenic substrate assay, because discrepancies between the two methods can occur with some missense mutations (such as CRM+ variants). Measuring FIX:Ag as well allows assessment of whether the CRM+ subtype (dysfunctional type) is present.

Step 2: F9 gene analysis — Sanger sequencing or NGS analysis of the 8 exons of the F9 gene and adjacent intron-exon junctions is performed. When FIX Leyden is suspected (history of spontaneous improvement after puberty), analysis including the promoter region (-6, -20, -26, etc.) is needed. When a large deletion is suspected, MLPA (multiplex ligation-dependent probe amplification) or CGH array is additionally performed.

Step 3: Inhibitor testing — The presence and titer (BU) of anti-FIX antibodies are measured by the Bethesda assay or the Nijmegen-modified Bethesda assay. Below 5 BU is classified as a low-titer inhibitor, and 5 or higher as a high-titer inhibitor. Because inhibitor development directly affects the treatment plan and prognosis, testing is performed at diagnosis and regularly after exposure to FIX products.

The differential diagnosis includes hemophilia A (decreased FVIII:C), FXI deficiency (decreased FXI:C, autosomal recessive), FX deficiency, vitamin K-dependent coagulation factor deficiency (combined decrease of FII/FVII/FIX/FX), and acquired hemophilia B (rarely, autoantibodies to FIX).

10. Treatment

Treatment of hemophilia B is divided into treatment of bleeding episodes (on-demand therapy) and preventive treatment (prophylaxis), and prophylaxis is currently recommended as standard treatment for severe and moderate patients.

FIX concentrates

Standard half-life (SHL) recombinant FIX products: BeneFIX (nonacog alfa, Pfizer), Rixubis (nonacog gamma, Takeda), Idelvion (standard half-life version). Half-life about 18–24 hours. For prophylaxis, intravenous injection 2–3 times a week.

Extended half-life (EHL) FIX products: Fc fusion, albumin fusion, and PEGylation technologies extend the half-life and reduce injection frequency.

Non-factor replacement therapies

Emicizumab (Hemlibra, Roche) is a bispecific antibody that binds FIXa and FX simultaneously, mimicking the function of FVIIIa. Because it does not directly replace FIX, it does not directly correct the FIX deficiency of hemophilia B, but it bypasses the downstream pathway and substitutes for the function of the tenase complex. It can be used instead of FIX products in hemophilia B patients who have developed inhibitors. It is given by subcutaneous injection once weekly, every other week, or once every 4 weeks.

Fitusiran (Alhemo) is an siRNA (small interfering RNA) therapeutic targeting antithrombin (AT). By reducing AT synthesis in the liver and thereby increasing thrombin generation, it can be applied to both hemophilia A and B regardless of inhibitor status. It is given by subcutaneous injection once a month. Its efficacy in hemophilia B was confirmed in the ATLAS clinical studies and in the 2023 NEJM paper by Mahlangu et al.

Gene therapy

In November 2022, the FDA approved etranacogene dezaparvovec (Hemgenix, CSL Behring) as the first gene therapy for hemophilia B. Hemgenix is an AAV5 vector expressing the FIX Padua variant (p.Arg338Leu) and aims at sustained FIX expression in hepatocytes after a single intravenous injection. In the HOPE-B clinical study, after a single dose the median FIX:C rose markedly from baseline to reach about 40%, the annual number of bleeds decreased by about 64%, and most patients were able to stop FIX prophylaxis. However, efficacy may be limited in patients with preexisting neutralizing antibodies to AAV5, and monitoring of long-term safety and durability of expression is ongoing.

Treatment of patients with inhibitors

In hemophilia B patients who have developed inhibitors, bypassing agents are used instead of FIX concentrates. Recombinant activated FVII (rFVIIa, NovoSeven, Novo Nordisk) and activated prothrombin complex concentrate (aPCC, FEIBA, Takeda) are the main bypassing agents. When ITI is attempted in hemophilia B, the success rate is low (lower than the about 70% in hemophilia A) and there is a risk of anaphylaxis and nephrotic syndrome, so the decision must be made carefully.

11. Prognosis

In the modern treatment setting, the prognosis of patients with hemophilia B has improved greatly. When prophylaxis is provided systematically and appropriate access to treatment is ensured, life expectancy has approached that of the general population. Sudden death from intracranial hemorrhage and severe disability from joint damage have also decreased markedly compared with the past.

Inhibitor development remains an important risk factor for prognosis in hemophilia B. Although the incidence is 3–5%, lower than in hemophilia A, treatment becomes complex when it occurs and long-term hemostatic management becomes difficult. Considering the low success rate of ITI and the risk of serious immune reactions in hemophilia B patients with inhibitors, an initial treatment strategy to prevent inhibitors is very important.

Patients with the FIX Leyden variant, despite a history of severe bleeding in childhood, maintain FIX:C at mild levels in adulthood and have a relatively good prognosis. After puberty, it is possible to reduce the intensity of prophylaxis or switch to on-demand treatment, and with appropriate management, a near-normal quality of life can be expected.

The incidence of hemophilic arthropathy has decreased greatly in the generation that received prophylaxis, but patients of earlier generations often already have progressive joint damage. In patients with existing joint damage, physical therapy, strengthening exercise, pain management, arthroscopy, synovectomy, or joint replacement may be needed.

With the clinical introduction of gene therapy (Hemgenix), some patients have been able to stop prophylaxis for long periods after a single dose. Monitoring of the long-term safety, durability of expression, and hepatotoxicity of gene therapy continues, and data are accumulating on whether the treatment effect lasts several years or more. If gene therapy becomes accessible to more patients in the long term, the prognosis of hemophilia B is expected to improve further.

12. Prevention

Prevention strategies for hemophilia B operate on two levels: genetic prevention (preventing transmission of the disease within the family) and clinical prevention of bleeding (prophylaxis).

Genetic counseling should be offered to patients with hemophilia B and their families. Provide information on the X-linked recessive mode of inheritance, the risk of an affected male child (50% for each pregnancy of a carrier female), the possibility of symptoms in female carriers (skewed X-chromosome inactivation), and reproductive options (prenatal diagnosis after natural conception, IVF with PGT, etc.).

Carrier testing is performed by F9 gene analysis in female first-degree relatives of patients with hemophilia B, such as mothers, sisters, and daughters. When the causative variant in the family is known, it can be performed efficiently with testing specific to that variant. FIX:C is also measured in carrier females to assess bleeding risk, and if needed, a FIX replacement plan is established before surgery or delivery.

Prenatal diagnosis is performed by obtaining fetal DNA through chorionic villus sampling (CVS) at 11–14 weeks of gestation or amniocentesis at 15–18 weeks of gestation and analyzing the F9 gene. Preimplantation genetic testing (PGT), combined with in vitro fertilization (IVF), checks for F9 gene abnormalities at the embryo stage and selectively transfers normal or carrier (female) embryos; its use is gradually increasing in hemophilia B families.

Primary prophylaxis aims to prevent hemophilic arthropathy by starting regular FIX infusions before the first joint bleed or before age 2. It is strongly recommended in patients with severe and moderate hemophilia B. The intensity and mode of prophylaxis (low dose, high frequency vs. standard dose, standard frequency vs. pharmacokinetics-based individualization) are decided considering the patient's age, activity level, difficulty of venous access, and preferences. Using EHL products allows longer dosing intervals while maintaining higher trough FIX:C levels, improving joint protection. Before any invasive procedure, a FIX replacement plan must be established in advance in collaboration with a specialized hemophilia team, and aspirin and nonselective NSAIDs should be avoided where possible because they impair platelet function and increase bleeding risk.

13. References

  1. Srivastava A, et al. WFH Guidelines for the Management of Haemophilia, 3rd ed. Haemophilia. 2020;26(S6):1-158.
  2. Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706-718.
  3. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
  4. Mahlangu J, Ragni MV, Gupta N, et al. Fitusiran prophylaxis in patients with haemophilia A or B. N Engl J Med. 2023;389(20):1843-1855.
  5. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science. 1992;257(5068):377-379.
  6. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2019;381(19):1811-1819.
  7. Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: defining patient benefit. Haemophilia. 2019;25(5):721-730.
  8. Biggs R, Douglas AS, Macfarlane RG, et al. Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952;2(4799):1378-1382.
  9. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA. 1982;79(21):6461-6464.
  10. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-1809.